Australian Pharmaceutical Industries Ltd (ASX:API) shares sink lower on soft full-year result

The Australian Pharmaceutical Industries Ltd (ASX:API) share price has drifted lower in morning trade following the release of a soft full year result. Here's what you need to know…

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In morning trade the Australian Pharmaceutical Industries Ltd (ASX: API) share price has drifted lower following the release of its full year results.

At the time of writing the pharmacy chain operator and wholesale distributor's shares are down 2% to $1.68.

Here is a summary of how the company performed in FY 2018 compared to a year earlier:

  • Revenue fell 0.9% to $4,026.3 million.
  • Priceline Pharmacy total network sales grew 2.1% to $2,110 million.
  • Underlying EBITDA was down 1.5% to $118.7 million.
  • Underlying net profit after tax up 0.9% to $54.7 million.
  • Total dividend up 0.5 cents to 7.5 cents per share.
  • Outlook: Earnings growth expected in FY 2019

Overall, I felt this was a soft result from Australian Pharmaceutical Industries and I can't say I'm surprised to see its shares drift lower today.

Management explained that total revenue fell slightly in FY 2018 due to a drop in demand for Hepatitis C medicines of approximately $155 million.

If you were to exclude Hepatitis C medicines from the equation, revenue would have increased by 3.3% on the prior corresponding period.

The decline in Hepatitis C medicines sales for its Pharmacy Distribution business offset the growth of its Priceline Pharmacy business. Priceline Pharmacy sales rose 2.1% to $2,110 million thanks to the addition of 13 new stores to its network. Like-for-like sales were down 0.2% during the period.

In respect to its decline in EBITDA, management has advised that this was due primarily to the impact of an increased number of price reduction cycles in the PBS during FY 2018 and exclusive direct distribution arrangements.

Looking ahead, management advised that it expects earnings growth in FY 2019. CEO Richard Vincent believes the business is positioned with the right assets to achieve that.

He said: "We are confident in the prospects of our different, complementary businesses and we have the management team and financial strength to accelerate the Clearskincare network, expand the scale of Consumer Brands, and develop our Priceline Pharmacy offer and the services to our independent network."

However, he has held back on giving any real guidance for FY 2019 with this release. Instead, he intends to wait for the conclusion of the Christmas trading period and the outcome of the CSO review before providing further guidance.

Should you invest?

Given the challenges that it faces and its low growth expectations over the coming years, I don't think Australian Pharmaceutical Industries' shares offer value for money right now.

Because of this, I intend to avoid them along with industry peers EBOS Group Ltd (ASX: EBO) and Sigma Healthcare Ltd (ASX: SIG).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Shot of a young businesswoman looking stressed out while working in an office.
Share Fallers

Why 29Metals, CAR Group, DroneShield, and Santana Minerals shares are falling today

These shares are missing out on the good times on Thursday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Imricor, Imugene, Newmont, and Pepper Money shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Cromwell Property, Metcash, Pilbara Minerals, and Tyro shares are falling today

Let's see why these shares are under pressure on Tuesday.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

Why Block, Computershare, South32, and Strickland Metals shares are falling today

These shares are starting the week in the red. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why CSL, Imricor, Jumbo, and Netwealth shares are falling today

These shares are under pressure on Thursday. But why?

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Share Fallers

Guess which ASX 200 stock is crashing 42% on big news

Big bad news is weighing heavily on this stock today.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Beetaloo, Botanix, Cobram Estate, and Origin Energy shares are falling today

These shares are having a poor session on Tuesday. But why?

Read more »